Mannose receptor (CD206) activation in tumor-associated macrophages enhances adaptive and innate antitumor immune responses
Jesse M. JaynesCollege of Agriculture, Environment and Nutrition Sciences, Integrative Biosciences Program, Tuskegee University, Tuskegee, AL 36088, USARushikesh SableRare Tumor Initiative, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USAMichael RonzettiNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850, USAWendy BautistaCenter for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD 21702, USAZachary KnottsRare Tumor Initiative, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USAAbisola Abisoye-OgunniyanDepartment of Biology and Center for Cancer Research, Tuskegee University, Tuskegee, AL 36088, USADandan LiRare Tumor Initiative, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USARaul CalvoNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850, USAMyagmarjav DashnyamNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850, USAAnju SinghNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850, USATheresa M. GuerinCenter for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD 21702, USAJason WhiteDepartment of Biology and Center for Cancer Research, Tuskegee University, Tuskegee, AL 36088, USASarangan RavichandranAdvanced Biomedical Computing Center, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD 21701, USAParimal KumarSequencing Facility and Single Cell Analysis Facility, Advanced Technology Research Facility, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21701, USAKeyur TalsaniaCCR-SF Bioinformatics Group, Advanced Biomedical and Computational Sciences, Biomedical Informatics and Data Science, Advanced Technology Research Facility, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21701, USAVicky ChenCCR-SF Bioinformatics Group, Advanced Biomedical and Computational Sciences, Biomedical Informatics and Data Science, Advanced Technology Research Facility, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21701, USAAnghesom GhebremedhinDepartment of Biology and Center for Cancer Research, Tuskegee University, Tuskegee, AL 36088, USABalasubramanyam KaranamDepartment of Biology and Center for Cancer Research, Tuskegee University, Tuskegee, AL 36088, USAAhmad Bin SalamDepartment of Biology and Center for Cancer Research, Tuskegee University, Tuskegee, AL 36088, USARuksana AminDepartment of Biology and Center for Cancer Research, Tuskegee University, Tuskegee, AL 36088, USATaivan OdzorigRare Tumor Initiative, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USATaylor AikenDepartment of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USAVictoria NguyenRare Tumor Initiative, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USAYansong BianCenter for Cancer ResearchJelani C. ZarifBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USAAmber E. de GrootDepartment of Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine, Baltimore, MD 21287, USAMonika MehtaSequencing Facility and Single Cell Analysis Facility, Advanced Technology Research Facility, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21701, USALixin FanBasic Science Program, Frederick National Laboratory for Cancer Research, SAXS Core Facility, Center for Cancer Research of the National Cancer Institute, Frederick, MD 21701, USAXin HuNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850, USAAnton SimeonovNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850, USANathan PateCenter for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD 21702, USAMones Abu‐AsabSection of Histopathology, National Eye Institute, Bethesda, MD 20892, USAMarc FerrerNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850, USANoel SouthallNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850, USAChan-Young OckDepartment of Hemato Oncology, Seoul National University Hospital, Seoul 03080, KoreaYongmei ZhaoCCR-SF Bioinformatics Group, Advanced Biomedical and Computational Sciences, Biomedical Informatics and Data Science, Advanced Technology Research Facility, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21701, USAHenry LopezMuriGenics Inc., Vallejo, CA 94592, USASerguei KozlovCenter for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD 21702, USANatalia de ValCancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD 21701, USAClayton YatesDepartment of Biology and Center for Cancer Research, Tuskegee University, Tuskegee, AL 36088, USABolormaa BaljinnyamNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850, USAJuan MarugánNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850, USA
2020en
ABI
Abstract
patient-derived xenotransplantation models. Mechanistically, via selective reduction of immunosuppressive M2-like TAMs, RP-182 improved adaptive and innate antitumor immune responses, including increased cancer cell phagocytosis by reprogrammed TAMs.
Identifiers
Citations and references
Cited by 20 references